

2<sup>nd</sup> World Congress on  
**BREAST CANCER**  
&  
**CANCER SCIENCE AND THERAPY**

September 16-17, 2019 | Edinburgh, Scotland

**Five day Accelerated Partial Breast Irradiation (APBI) using Stereotactic Body Radiation Therapy (SBRT) in stage 0-II breast cancer: A preliminary report of 69 cases**

**Valerie Gorman**

Baylor Scott and White Medical Center, USA

**Background:** Randomized trials in Stage 0-II breast cancer with 10 year follow-up have proven that Accelerated Partial Breast Irradiation (APBI) given via radiation implant in 5 days is equivalent to Whole Breast Radiation Therapy (WBRT) in 6 weeks in regard to tumor local recurrence (LR). However, implants are invasive and complications, including infection and soft tissue necrosis requiring possible mastectomy have been significant. Recently APBI using non-invasive Intensity Modulated Radiation Therapy (IMRT) in 5 days was shown to be equivalent to WBRT in 6 weeks with 5 year follow-up, with respect to LR [4]. APBI IMRT was superior in regard to side effects, and cosmesis.

**Objectives:** In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of individual fiducial markers bordering the surgical cavity. We have used the simpler less labor intensive Biozorb fiducial system to localize the CTV for SBRT.

**Materials and Methods:** Between 2017 and 2019, 69 patients underwent SBRT targeted to Biozorb defined CTV. Eligible patients were older than age 40, had tumor sizes < 3 cm, negative surgical margins, and negative node dissections. SBRT dose was 30 Gy given in 5 fractions. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV = CTV + 1-2 cm.

**Results:** Follow-up ranged from 1-18 months with a median of 9 months. LR has been 0% (0/69). There were no skin reactions. Cosmetic results were rated excellent in 100% (69/69) of cases.

**Conclusions:** Non-invasive APBI with SBRT given over 5 days targeted to Biozorb has resulted in LR, complications, and cosmetic results which compare favorably to invasive APBI given via implant. At last follow-up, there have been no LR, skin reactions, or complications. Cosmesis has been excellent in 100% of patients.

**Biography**

Valerie Gorman, MD, FACS is a breast surgeon who specializes in surgical oncology and surgical diseases of the breast. She is board certified by the American Board of Surgery and is a fellow of the American College of Surgeons. Gorman served as Chief of Oncology at Baylor Scott & White Medical Center - Waxahachie for eight years and currently serves there as Chief of Surgery and Medical Director of Surgical Services. Gorman has been in private practice in Texas since 2004.

valerie.gorman@bswhealth.org